Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 2Thoracic 1Lymphoid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Transitional Cell 29Urinary Bladder Neoplasms 26Carcinoma, Renal Cell 22Carcinoma, Non-Small-Cell Lung 10Neoplasms 7Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Ureteral Neoplasms 5Prostatic Neoplasms 5Ovarian Neoplasms 5Melanoma 5Carcinoma, Merkel Cell 5Urethral Neoplasms 4Triple Negative Breast Neoplasms 4Stomach Neoplasms 4Small Cell Lung Carcinoma 3Kidney Neoplasms 3Colorectal Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uterine Cervical Neoplasms 2Penile Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Lung Neoplasms 2Kidney Diseases 2Head and Neck Neoplasms 2Urothelial Cancer 1Urologic Neoplasms 1Turcot syndrome 1Testicular Neoplasms 1

Interventions

Peripheral Blood Stem Cell Transplantation 6Cyclophosphamide 6fludarabine phosphate 5Nivolumab 5Mycophenolic Acid 5Carboplatin 5Whole-Body Irradiation 4Radiotherapy 4Filgrastim 4Cyclosporine 4Gemcitabine 3Cisplatin 3Busulfan 3Antilymphocyte Serum 3cabozantinib 2cabazitaxel 2Voriconazole 2Thiotepa 2Therapeutics 2Standard of Care 2Sirolimus 2Polymerase Chain Reaction 2Mitomycin 2Methylprednisolone 2Methotrexate 2Melphalan 2Itraconazole 2Immunoglobulin G 2Goserelin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrence × avelumab × Genitourinary × Clear all
NCT03861403 2023-11-30

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Leap Therapeutics, Inc.

Phase 1 Terminated
10 enrolled
BreastGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡